{"id":10226,"date":"2026-07-15T10:14:43","date_gmt":"2026-07-15T08:14:43","guid":{"rendered":"https:\/\/cleanpeptides.eu\/kpv-doseringsguide\/"},"modified":"2026-07-15T10:14:43","modified_gmt":"2026-07-15T08:14:43","slug":"kpv-doseringsguide","status":"publish","type":"page","link":"https:\/\/cleanpeptides.eu\/da\/kpv-doseringsguide\/","title":{"rendered":"KPV doseringsguide: oral, subkutan og topisk"},"content":{"rendered":"<p class=\"wp-block-paragraph\"><em>KPV (Lys-Pro-Val) \u2014 det minimale antiinflammatoriske fragment af \u03b1-MSH. Oral, subkutan og topisk dosering til tarm og hud, NF-\u03baB-h\u00e6mning og sikkerhed. Kun til forskningsform\u00e5l \u2014 ikke til human brug.<\/em><\/p>\n<p class=\"wp-block-paragraph\">Clean Peptides giver ikke r\u00e5dgivning om dosering eller anvendelse. Denne guide samler produktinformation fra Clean Peptides sammen med uafh\u00e6ngigt undervisningsmateriale fra PeptideWiki, kun som forskningsreference. Det er ikke medicinsk r\u00e5dgivning og udg\u00f8r hverken anbefalinger, godkendelser eller instruktioner fra Clean Peptides.<\/p>\n<h2 class=\"wp-block-heading\">Hvad er KPV?<\/h2>\n<p class=\"wp-block-paragraph\">KPV (Lys-Pro-Val) er et naturligt forekommende tripeptid afledt af den C-terminale sekvens af alfa-melanocytstimulerende hormon (\u03b1-MSH) \u2014 det mindste fragment, der bevarer potent antiinflammatorisk aktivitet. KPV tr\u00e6nger ind i celler og h\u00e6mmer direkte NF-\u03baB&#8217;s nukleare translokation, hovedkontakten der styrer proinflammatoriske cytokiner (TNF-\u03b1, IL-6, IL-1\u03b2). I mods\u00e6tning til melanocortin-stimulerende peptider (f.eks. MT-II) er KPV rent antiinflammatorisk \u2014 ingen solbr\u00e6ndings-, seksuelle eller appetiteffekter. Dets lille st\u00f8rrelse kan tillade delvis oral optagelse, hvilket g\u00f8r oral dosering popul\u00e6r til tarmrettet bet\u00e6ndelse.<\/p>\n<p class=\"wp-block-paragraph\">Doseringen stammer fra pr\u00e6kliniske studier og protokoller fra f\u00e6llesskabet.<\/p>\n<h2 class=\"wp-block-heading\">N\u00f8gleegenskaber<\/h2>\n<ul class=\"wp-block-list\">\n<li>Minimalt antiinflammatorisk fragment af \u03b1-MSH \u2014 sekvensen Lys-Pro-Val.<\/li>\n<li>NF-\u03baB-h\u00e6mning \u2014 reducerer TNF-\u03b1, IL-6, IL-1\u03b2 og andre proinflammatoriske cytokiner.<\/li>\n<li>IKKE en melanocortinagonist \u2014 ingen solbr\u00e6ndings-, seksuelle eller appetiteffekter.<\/li>\n<li>Flere veje \u2014 oral (mest popul\u00e6r til tarm), subkutan, topisk, intranasal.<\/li>\n<li>Potentiel oral biotilg\u00e6ngelighed \u2014 tripeptidst\u00f8rrelsen kan tillade en vis GI-optagelse.<\/li>\n<li>Meget mild bivirkningsprofil \u2014 ingen hormonp\u00e5virkning eller receptordesensibilisering.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">S\u00e5dan fastl\u00e6gges doseringen<\/h2>\n<p class=\"wp-block-paragraph\">Baseret p\u00e5 pr\u00e6kliniske IBD- og hudbet\u00e6ndelsesmodeller (Dalmasso et al.; Kannengiesser et al.) og brug i f\u00e6llesskabet. Dyredoser i mikrogram\/kg blev ekstrapoleret til det orale interval p\u00e5 200\u2013500 mcg. Evidensstyrke: moderat pr\u00e6klinisk, begr\u00e6nset klinisk.<\/p>\n<h2 class=\"wp-block-heading\">Standarddoseringsintervaller<\/h2>\n<h3 class=\"wp-block-heading\">Oral<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Niveau<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dosis<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Hyppighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dagligt total<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Bem\u00e6rkninger<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Start<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u00d7 dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Tom mave; vurd\u00e9r tolerance<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standard<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200\u2013500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u20132\u00d7 dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200\u20131000 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Mest almindeligt ved tarmbet\u00e6ndelse \/ IBD<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00f8jere interval<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u00d7 dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1000 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Vedvarende bet\u00e6ndelse<\/td>\n<\/tr>\n<\/table>\n<h3 class=\"wp-block-heading\">Subkutan<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Niveau<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dosis<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Hyppighed<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Dagligt total<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Bem\u00e6rkninger<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Start<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u00d7 dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Vurd\u00e9r tolerance; skift steder<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standard<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200\u2013300 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u00d7 dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200\u2013300 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Systemisk antiinflammatorisk<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00f8jere interval<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1\u00d7 dagligt<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Aktive inflammatoriske tilstande<\/td>\n<\/tr>\n<\/table>\n<h3 class=\"wp-block-heading\">Topisk<\/h3>\n<p class=\"wp-block-paragraph\">Rekonstitueret og p\u00e5f\u00f8rt den ber\u00f8rte hud 1\u20132\u00d7 dagligt, eller magistrelt fremstillet i en creme\/gel. Bedst til lokaliseret hudbet\u00e6ndelse (dermatitis, eksem, psoriasis, s\u00e5rheling).<\/p>\n<h3 class=\"wp-block-heading\">Sammenligning af administrationsveje<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Parameter<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Oral<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Subkutan<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Topisk<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Intranasal<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Typisk dosis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">200\u2013500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100\u2013500 mcg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">P\u00e5f\u00f8rt omr\u00e5det<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">100\u2013200 mcg<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Biotilg\u00e6ngelighed<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Lavere (delvis)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">H\u00f8jest<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Lokal<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Moderat<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Bedst til<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Tarm, IBD<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Systemisk<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Hudtilstande<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Bihuler \/ luftveje<\/td>\n<\/tr>\n<\/table>\n<h2 class=\"wp-block-heading\">Rekonstituering og dosering (med de medf\u00f8lgende 3 mL)<\/h2>\n<p class=\"wp-block-paragraph\">Hos Clean Peptides leveres KPV som en del af <a href=\"https:\/\/cleanpeptides.eu\/da\/klow-pen-doseringsguide\/\">KLOW-blandingen<\/a> frem for som et selvst\u00e6ndigt h\u00e6tteglas; tallene nedenfor bruger et typisk selvst\u00e6ndigt 5 mg-h\u00e6tteglas som reference. Oral KPV doseres fra forudm\u00e5lte kapsler og kr\u00e6ver ingen rekonstituering.<\/p>\n<p class=\"wp-block-paragraph\">Hvert Clean Peptides-h\u00e6tteglas leveres med 3 mL bakteriostatisk vand (0,9 % benzylalkohol). Alle tal nedenfor foruds\u00e6tter rekonstituering med de fulde 3 mL. P\u00e5 en standard U-100-insulinspr\u00f8jte er 100 enheder = 1 mL. Hurtig formel: koncentration = h\u00e6tteglasstyrke \u00f7 3 mL, og enheder at tr\u00e6kke op = dosis (mg) \u00d7 300 \u00f7 h\u00e6tteglasstyrke (mg).<\/p>\n<h3 class=\"wp-block-heading\">S\u00e5dan rekonstitueres<\/h3>\n<ol class=\"wp-block-list\">\n<li>Vask h\u00e6nderne og l\u00e6g h\u00e6tteglasset, de 3 mL bakteriostatisk vand, en insulinspr\u00f8jte og spritservietter frem p\u00e5 en ren overflade.<\/li>\n<li>Vip h\u00e6tterne af og aft\u00f8r begge gummipropper med sprit; lad dem luftt\u00f8rre 10\u201315 sekunder.<\/li>\n<li>Tr\u00e6k de fulde 3 mL bakteriostatisk vand op (i tre 1 mL-omgange med en insulinspr\u00f8jte eller i \u00e9n omgang med en 3 mL-spr\u00f8jte).<\/li>\n<li>Tils\u00e6t vandet langsomt, og vinkl n\u00e5len, s\u00e5 det l\u00f8ber ned ad den indvendige glasv\u00e6g \u2014 spr\u00f8jt det aldrig direkte p\u00e5 pulveret.<\/li>\n<li>Opl\u00f8s forsigtigt \u2014 lad h\u00e6tteglasset st\u00e5 1\u20132 minutter, og hvirvl eller rul det derefter mellem h\u00e5ndfladerne, til opl\u00f8sningen er klar. Ryst aldrig.<\/li>\n<li>M\u00e6rk og opbevar i k\u00f8leskab ved 2\u20138 \u00b0C. Resulterende koncentration: 5 mg \u2192 1,67 mg\/mL.<\/li>\n<\/ol>\n<p class=\"wp-block-paragraph\"><strong>Opbevaring:<\/strong> ikke-rekonstitueret pulver i k\u00f8leskab (2\u20138 \u00b0C); rekonstitueret opl\u00f8sning i k\u00f8leskab og anvendt inden for 28\u201330 dage; m\u00e5 ikke fryses; beskyt mod lys og varme.<\/p>\n<h3 class=\"wp-block-heading\">Optr\u00e6ksvolumener med 3 mL \u2014 KPV<\/h3>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">H\u00e6tteglas (Clean Peptides)<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Koncentration<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">200 mcg<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">300 mcg<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">500 mcg<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">5 mg<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">1,67 mg\/mL<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">12 e<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">18 e<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">30 e<\/td>\n<\/tr>\n<\/table>\n<h2 class=\"wp-block-heading\">Dosering efter m\u00e5l<\/h2>\n<ul class=\"wp-block-list\">\n<li><strong>Tarmbet\u00e6ndelse og IBD:<\/strong> oral 200\u2013500 mcg 1\u20132\u00d7 dagligt, p\u00e5 tom mave, 4\u20138 uger. Kombin\u00e9r med BPC-157 til slimhindereparation (den mest popul\u00e6re KPV-kombination).<\/li>\n<li><strong>Hudbet\u00e6ndelse:<\/strong> topisk 1\u20132\u00d7 dagligt; eventuelt oral 200\u2013500 mcg dagligt til systemisk st\u00f8tte.<\/li>\n<li><strong>Systemisk bet\u00e6ndelse:<\/strong> SC 200\u2013500 mcg en gang dagligt, 4\u20138 uger; overvej thymosin alpha-1.<\/li>\n<li><strong>S\u00e5rheling:<\/strong> topisk p\u00e5 stedet \u00b1 SC 200\u2013300 mcg dagligt; 2\u20136 uger. Kombin\u00e9r med BPC-157 + TB-500.<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Match vejen til m\u00e5let: oral til tarm, SC til systemisk, topisk til hud.<\/p>\n<h2 class=\"wp-block-heading\">Cyklus og varighed<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:1em 0;\">\n<tr>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Protokol<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Aktiv periode<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Pauseperiode<\/th>\n<th style=\"background:#f4f4f4;border:1px solid #ddd;padding:8px;text-align:left;\">Bem\u00e6rkninger<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Standard (tarm)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">4\u20138 uger<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u20134 ugers pause<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Revurd\u00e9r symptomer ved 4 uger<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Forl\u00e6nget (kronisk IBD)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">8\u201312 uger<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">4 ugers pause<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Overv\u00e5g og revurd\u00e9r regelm\u00e6ssigt<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Vedligeholdelse<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">L\u00f8bende ved lavere dosis<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">N\/A<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">~200 mcg\/dag; begr\u00e6nsede langtidsdata<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #ddd;padding:8px;\">Akut (s\u00e5rheling)<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">2\u20136 uger<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Stop n\u00e5r helet<\/td>\n<td style=\"border:1px solid #ddd;padding:8px;\">Matcher helingsforl\u00f8bet<\/td>\n<\/tr>\n<\/table>\n<p class=\"wp-block-paragraph\">Lavere risiko for desensibilisering end GHRP&#8217;er (intracellul\u00e6r NF-\u03baB-mekanisme), men cyklus er stadig bedste praksis.<\/p>\n<h2 class=\"wp-block-heading\">Kombinationsprotokoller<\/h2>\n<p class=\"wp-block-paragraph\"><strong>KPV + BPC-157 (tarmhelingskombination, mest popul\u00e6r):<\/strong> KPV 200\u2013500 mcg oral 1\u20132\u00d7 dagligt (NF-\u03baB-h\u00e6mning) + BPC-157 250\u2013500 mcg oral eller SC (slimhindereparation).<\/p>\n<p class=\"wp-block-paragraph\">Fulde BPC-157-protokoller: se vores <a href=\"https:\/\/cleanpeptides.eu\/da\/bpc-157-doseringsguide\/\">BPC-157-doseringsguide<\/a>. Andre kombinationer: KPV + LL-37 (antiinflammatorisk + antimikrobiel); KPV + thymosin alpha-1 (immunmodulation); KPV + BPC-157 + <a href=\"https:\/\/cleanpeptides.eu\/da\/tb-500-doseringsguide\/\">TB-500<\/a> (omfattende heling). KPV interagerer ikke med melanocortinveje.<\/p>\n<h2 class=\"wp-block-heading\">Sikkerhed, bivirkninger og kontraindikationer<\/h2>\n<p class=\"wp-block-paragraph\">En af de mildeste bivirkningsprofiler blandt forskningspeptider; ingen hormonp\u00e5virkning, ingen receptordesensibilisering.<\/p>\n<p class=\"wp-block-paragraph\"><strong>Sj\u00e6ldne, milde:<\/strong> GI-ubehag (oral), reaktioner ved injektionsstedet (SC), sj\u00e6lden hovedpine, mild hudirritation (topisk).<\/p>\n<p class=\"wp-block-paragraph\"><strong>Kontraindikationer:<\/strong> graviditet og amning; forsigtighed ved aktiv alvorlig infektion (NF-\u03baB har en rolle i immunforsvaret); immunsv\u00e6kkede personer; kendt overf\u00f8lsomhed.<\/p>\n<p class=\"wp-block-paragraph\">Ikke FDA-godkendt; forskningspeptid (i nogle jurisdiktioner solgt som kosttilskud).<\/p>\n<h2 class=\"wp-block-heading\">Almindelige fejl<\/h2>\n<ul class=\"wp-block-list\">\n<li>At forvente melanocortineffekter (solbr\u00e6ndthed\/libido\/appetit) \u2014 KPV har ingen.<\/li>\n<li>At bruge injicerbare doser oralt eller omvendt.<\/li>\n<li>At stoppe for tidligt (tarmforbedring tager 1\u20132 uger; fuld IBD-effekt 4\u20138 uger).<\/li>\n<li>At bruge KPV alene til sv\u00e6r IBD uden l\u00e6geligt tilsyn.<\/li>\n<li>Forkert opbevaring af den rekonstituerede opl\u00f8sning.<\/li>\n<li>At tage oral KPV med et stort m\u00e5ltid.<\/li>\n<li>At forveksle KPV med fuldl\u00e6ngde alfa-MSH.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Hovedpunkter<\/h2>\n<ul class=\"wp-block-list\">\n<li>Minimalt antiinflammatorisk fragment af \u03b1-MSH, der virker via NF-\u03baB-h\u00e6mning (ikke via melanocortinreceptorer).<\/li>\n<li>Ingen solbr\u00e6ndings-, seksuelle eller appetiteffekter.<\/li>\n<li>Oral 200\u2013500 mcg 1\u20132\u00d7 dagligt (tom mave) er mest popul\u00e6r; SC 100\u2013500 mcg til systemisk; topisk til hud.<\/li>\n<li>Guldstandard-kombination: KPV + BPC-157 til tarm\/IBD.<\/li>\n<li>Cyklus 4\u20138 uger; meget milde bivirkninger; ikke FDA-godkendt.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Referencer<\/h2>\n<ol class=\"wp-block-list\">\n<li>Dalmasso G, et al. &#8220;PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.&#8221; Gastroenterology. 2008;134(1):166-178.<\/li>\n<li>Kannengiesser K, et al. &#8220;Melanocortin-derived tripeptide KPV has anti-inflammatory potential in IBD models.&#8221; Inflamm Bowel Dis. 2008;14(3):324-331.<\/li>\n<li>Brzoska T, et al. &#8220;Alpha-MSH and related tripeptides: anti-inflammatory and protective effects.&#8221; Endocr Rev. 2008;29(5):581-602.<\/li>\n<li>Luger TA, et al. &#8220;Functions of alpha-MSH and related peptides in the immune system.&#8221; Ann N Y Acad Sci. 2003;994:133-140.<\/li>\n<li>Ichiyama T, et al. &#8220;Alpha-MSH inhibits NF-\u03baB activation.&#8221; Exp Neurol. 1999;157(2):359-365.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Download og relaterede ressourcer<\/h2>\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/cleanpeptides.eu\/wp-content\/uploads\/2026\/07\/05-KPV-Dosage-Guide-Clean-Peptides.pdf\" target=\"_blank\" rel=\"noopener\">\ud83d\udcc4 Download den fulde PDF-guide<\/a><\/p>\n<p class=\"wp-block-paragraph\">K\u00f8b: <a href=\"https:\/\/cleanpeptides.eu\/product\/klow-pen-80-mg-bpc-157-tb-500-ghk-cu-kpv\/\">KLOW Pen 80 mg<\/a> (indeholder KPV). Relaterede guider: <a href=\"https:\/\/cleanpeptides.eu\/da\/bpc-157-doseringsguide\/\">BPC-157<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/da\/tb-500-doseringsguide\/\">TB-500<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/da\/ghk-cu-doseringsguide\/\">GHK-Cu<\/a> \u00b7 <a href=\"https:\/\/cleanpeptides.eu\/da\/klow-pen-doseringsguide\/\">KLOW Pen 80 mg<\/a>.<\/p>\n\n    <div class=\"xs_social_share_widget xs_share_url after_content \t\tmain_content  wslu-style-1 wslu-share-box-shaped wslu-fill-colored wslu-none wslu-share-horizontal wslu-theme-font-no wslu-main_content\">\n\n\t\t\n        <ul>\n\t\t\t        <\/ul>\n    <\/div> \n","protected":false},"excerpt":{"rendered":"<p>KPV (Lys-Pro-Val) \u2014 det minimale antiinflammatoriske fragment af \u03b1-MSH. Oral, subkutan og topisk dosering til tarm og hud, NF-\u03baB-h\u00e6mning og [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-10226","page","type-page","status-publish","hentry"],"_hostinger_reach_plugin_has_subscription_block":false,"_hostinger_reach_plugin_is_elementor":false,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/comments?post=10226"}],"version-history":[{"count":0,"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/pages\/10226\/revisions"}],"wp:attachment":[{"href":"https:\/\/cleanpeptides.eu\/da\/wp-json\/wp\/v2\/media?parent=10226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}